Ghana Secures 5-Year Deal To Use Novartis’ Drug For Sickle Cell Treatment
Ghana will use hydroxyurea, a generic drug developed by Novartis, for the treatment of Sickle Cell Disease (SCD) following a five-year agreement signed in January this year.
The treatment, according to the Ghana Health Service, will soon…
Read More...
Read More...